Journal
VACCINE
Volume 18, Issue 17, Pages 1743-1754Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S0264-410X(99)00530-7
Keywords
PspA; Streptococcus; pneumococcus
Categories
Funding
- NHLBI NIH HHS [HL58418] Funding Source: Medline
- NIAID NIH HHS [AI-21548, AI-40645] Funding Source: Medline
Ask authors/readers for more resources
Pneumococcal surface protein A (PspA) is a highly variable protein found on all strains of pneumococci. To be successful, a PspA-based vaccine for S. pneumoniae must induce antibodies that are broadly cross-reactive. To address whether cross-reactive antibodies could be induced in man, we evaluated serum from adults immunized with recombinant clade 2 PspA from strain Rx1. Immunization with 5-125 mu g rPspA lead to a significant increase in circulating anti-PspA antibodies, as well as antibodies reactive to heterologous rPspA molecules. Increased binding of post-immune sera to 37 pneumococcal strains expressing a variety of PspA and capsule types was observed, Versus pre-immune sera. The extent of cross-clade reactivity of human anti-rPspA followed roughly the amount of sequence homology to the non-clade 2 antigens. It is hypothesized that priming of humans by natural exposure to S. pneumoniae contributes to the breadth of the cross-reactivity of antibody to PspA. (C) 2000 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available